195 related articles for article (PubMed ID: 14729632)
1. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
Boulay A; Zumstein-Mecker S; Stephan C; Beuvink I; Zilbermann F; Haller R; Tobler S; Heusser C; O'Reilly T; Stolz B; Marti A; Thomas G; Lane HA
Cancer Res; 2004 Jan; 64(1):252-61. PubMed ID: 14729632
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Tanaka C; O'Reilly T; Kovarik JM; Shand N; Hazell K; Judson I; Raymond E; Zumstein-Mecker S; Stephan C; Boulay A; Hattenberger M; Thomas G; Lane HA
J Clin Oncol; 2008 Apr; 26(10):1596-602. PubMed ID: 18332467
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
Advani AS; Mahfouz RZ; Maciejewski J; Rybicki L; Sekeres M; Tripp B; Kalaycio M; Bates J; Saunthararajah Y
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):172-177.e1. PubMed ID: 24332215
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
[TBL] [Abstract][Full Text] [Related]
6. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
7. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
[TBL] [Abstract][Full Text] [Related]
8. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
11. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
Hjelmeland AB; Lattimore KP; Fee BE; Shi Q; Wickman S; Keir ST; Hjelmeland MD; Batt D; Bigner DD; Friedman HS; Rich JN
Mol Cancer Ther; 2007 Sep; 6(9):2449-57. PubMed ID: 17766837
[TBL] [Abstract][Full Text] [Related]
12. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors.
Okamoto I; Doi T; Ohtsu A; Miyazaki M; Tsuya A; Kurei K; Kobayashi K; Nakagawa K
Jpn J Clin Oncol; 2010 Jan; 40(1):17-23. PubMed ID: 19783551
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
16. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
18. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
19. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
